SCHEMBL2196969

SCHEMBL2196969

N#Cc1cccc2c1CC[C@H]2O

nearest known ligand 0.50

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 1/20 0.50
DRD2 P14416 2/20 0.45
CYP11B1 P15538 2/20 0.43
CYP11B2 P19099 2/20 0.43
S1PR1 P21453 4/20 0.41
DRD1 P21728 1/20 0.41
DRD4 P21917 1/20 0.41
DRD5 P21918 1/20 0.41
EPAS1 Q99814 1/20 0.38
PGR P06401 1/20 0.38
KDM4E B2RXH2 1/20 0.38
ALDH1A1 P00352 1/20 0.38
POLL Q9UGP5 1/20 0.37
NOTUM Q6P988 1/20 0.37
ADRA1A P35348 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29529595 1.00 KMT2A (0.50) KMT2ADRD2CYP11B1CYP11B2S1PR1
SCHEMBL1413268 1.00 KMT2A (0.50) KMT2ADRD2CYP11B1CYP11B2S1PR1
SCHEMBL5784676 1.00 KMT2A (0.50) KMT2ADRD2CYP11B1CYP11B2S1PR1
SCHEMBL31181835 1.00 KMT2A (0.50) KMT2ADRD2CYP11B1CYP11B2S1PR1
SCHEMBL2195961 1.00 KMT2A (0.50) KMT2ADRD2CYP11B1CYP11B2S1PR1
SCHEMBL1879002 0.89 KMT2A (0.61) KMT2ADRD2CYP11B1CYP11B2S1PR1
SCHEMBL1879606 0.89 KMT2A (0.61) KMT2ADRD2CYP11B1CYP11B2S1PR1
SCHEMBL29741068 0.89 KMT2A (0.61) KMT2ADRD2CYP11B1CYP11B2S1PR1
SCHEMBL1872298 0.89 KMT2A (0.61) KMT2ADRD2CYP11B1CYP11B2S1PR1
SCHEMBL23782820 0.79 EPAS1 (0.45) KMT2ACYP11B1CYP11B2S1PR1EPAS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110256288-A A method of preparing (S) -1- amino -2,3- dihydro -1H- indenes -4- formonitrile HCN 苏州山青竹生物医药有限公司 2019-09-20 CN claimed
US-20260125359-A1 HETEROARYL COMPOUNDS AS MULTI-TARGET PROTEIN KINASE INHIBITORS FUJIAN HAIXI PHARMACEUTICALS CO LTD (CN) 2026-05-07 US disclosed
EP-3518922-B1 COMPOUNDS AND METHODS FOR TREATING LUPUS RECEPTOS LLC (US) 2026-02-11 EP disclosed
EP-3856738-B1 PROCESS FOR THE PREPARATION OF SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONIST QUIM SINTETICA S A (ES) 2025-03-19 EP disclosed
EP-2498610-B2 SELECTIVE SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS AND METHODS OF CHIRAL SYNTHESIS RECEPTOS LLC (US) 2024-06-19 EP disclosed
US-11465977-B2 Process for the preparation of sphingosine-1-phosphate receptor agonist Química Sintética, S.A. (ES) 2022-10-11 US disclosed
US-11278526-B2 Compounds and methods for treating lupus RECEPTOS LLC (US) 2022-03-22 US disclosed
US-20220033365-A1 PROCESS FOR THE PREPARATION OF SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONIST Química Sintética, S.A. (ES) 2022-02-03 US disclosed
US-20220033365-A1 PROCESS FOR THE PREPARATION OF SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONIST Química Sintética, S.A. (ES) 2022-02-03 US disclosed
CN-113698319-A Preparation method of ozapimod intermediate 偶极医药科技(徐州)有限公司 2021-11-26 CN disclosed
CN-102762100-B Selective sphingosine-1-phosphate receptor modulators and chiral synthesis methods RECEPTOS INC 2015-07-01 CN disclosed
WO-2015066515-A1 SELECTIVE SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS AND COMBINATION THERAPY THEREWITH RECEPTOS, INC. (US) 2015-05-07 WO disclosed
US-20130231326-A1 SELECTIVE SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS AND METHODS OF CHIRAL SYNTHESIS RECEPTOS, INC. (US) 2013-09-05 US disclosed
US-20130231326-A1 SELECTIVE SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS AND METHODS OF CHIRAL SYNTHESIS RECEPTOS, INC. (US) 2013-09-05 US disclosed
US-8362048-B2 Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis RECEPTOS, INC. (US) 2013-01-29 US disclosed
US-8362048-B2 Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis RECEPTOS, INC. (US) 2013-01-29 US disclosed
CN-102762100-A Selective sphingosine-1-phosphate receptor modulators and chiral synthesis methods RECEPTOS INC 2012-10-31 CN disclosed
US-20110172202-A1 SELECTIVE SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS AND METHODS OF CHIRAL SYNTHESIS RECEPTOS LLC 2011-07-14 US disclosed
US-20110172202-A1 SELECTIVE SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS AND METHODS OF CHIRAL SYNTHESIS RECEPTOS LLC 2011-07-14 US disclosed
WO-2011060392-A1 SELECTIVE SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS AND METHODS OF CHIRAL SYNTHESIS RECEPTOS, INC. (US) 2011-05-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11278526-B2 Compounds and methods for treating lupus S1PR1, S1PR2, SSB KMT2A 1801/4885DRD2 3747/4885CYP11B1 1537/4885
US-20110172202-A1 SELECTIVE SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS AND METHODS OF CHIRAL SYNTHESIS S1PR1, S1PR3, S1PR2 KMT2A 4226/4885DRD2 2358/4885CYP11B1 519/4885
US-20220033365-A1 PROCESS FOR THE PREPARATION OF SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONIST S1PR1, S1PR4, S1PR3 KMT2A 3393/4885DRD2 1733/4885CYP11B1 1525/4885
US-20260125359-A1 HETEROARYL COMPOUNDS AS MULTI-TARGET PROTEIN KINASE INHIBITORS ERBB2, ERBB3, ARRB1 KMT2A 2787/4885DRD2 3071/4885CYP11B1 644/4885
US-11465977-B2 Process for the preparation of sphingosine-1-phosphate receptor agonist S1PR1, S1PR4, S1PR3 KMT2A 3393/4885DRD2 1733/4885CYP11B1 1525/4885
US-20130231326-A1 SELECTIVE SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS AND METHODS OF CHIRAL SYNTHESIS S1PR1, S1PR3, S1PR2 KMT2A 4230/4885DRD2 2353/4885CYP11B1 492/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.